R Bagatell

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. ncbi request reprint Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin
    Rochelle Bagatell
    Steele Memorial Children s Research Center and The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Int J Cancer 113:179-88. 2005
  2. ncbi request reprint Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer
    R Bagatell
    Department of Pediatrics, Steele Memorial Children s Research Center, University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 7:2076-84. 2001
  3. ncbi request reprint Two cases of pediatric neuroblastoma with tumor thrombus in the inferior vena cava
    Rochelle Bagatell
    Department of Pediatrics and Steele Memorial Children s Research Center, Tucson, Arizona, USA
    J Pediatr Hematol Oncol 24:397-400. 2002
  4. ncbi request reprint When children die: a seminar series for pediatric residents
    Rochelle Bagatell
    Department of Pediatrics, Steele Memorial Children s Research Center, University of Arizona, Tucson, Arizona 85724, USA
    Pediatrics 110:348-53. 2002
  5. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study
    Rochelle Bagatell
    Department of Pediatrics and Steele Children s Research Center, University of Arizona, Tucson, AZ 85724, USA
    Clin Cancer Res 13:1783-8. 2007
  6. ncbi request reprint The perfect storm: Torsades de Pointes in a child with leukemia
    Rochelle Bagatell
    Department of Pediatrics, Section of Pediatric Hematology Oncology, University of Arizona Health Sciences Center, Tucson, Arizona 85724, USA
    Pediatr Blood Cancer 49:996-9. 2007
  7. ncbi request reprint Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy
    Rochelle Bagatell
    University of Arizona, Department of Pediatrics and Steele Children s Research Center, Tuscon, AZ, USA
    J Clin Oncol 23:8819-27. 2005
  8. ncbi request reprint Altered Hsp90 function in cancer: a unique therapeutic opportunity
    Rochelle Bagatell
    Department of Pediatrics and Hematology Oncology, Arizona Health Sciences Center, Room 5341, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
    Mol Cancer Ther 3:1021-30. 2004
  9. ncbi request reprint Inhibition of oncogene expression using vector-generated RNA antisense
    L Whitesell
    Department of Pediatrics, University of Arizona, Tucson, Arizona 85724, USA
    Methods 18:296-303. 1999
  10. ncbi request reprint The stress response: implications for the clinical development of hsp90 inhibitors
    Luke Whitesell
    Steele Memorial Children s Research Center, University of Arizona, Tucson, AZ 85724, USA
    Curr Cancer Drug Targets 3:349-58. 2003

Research Grants

Detail Information

Publications20

  1. ncbi request reprint Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin
    Rochelle Bagatell
    Steele Memorial Children s Research Center and The Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Int J Cancer 113:179-88. 2005
    ..Our findings suggest that Hsp90 inhibitors may prove useful either alone or as a component of multi-drug regimens in the treatment of neuroblastoma and osteosarcoma...
  2. ncbi request reprint Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer
    R Bagatell
    Department of Pediatrics, Steele Memorial Children s Research Center, University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 7:2076-84. 2001
    ....
  3. ncbi request reprint Two cases of pediatric neuroblastoma with tumor thrombus in the inferior vena cava
    Rochelle Bagatell
    Department of Pediatrics and Steele Memorial Children s Research Center, Tucson, Arizona, USA
    J Pediatr Hematol Oncol 24:397-400. 2002
    ..In one patient a pulmonary embolus developed after initiation of cytotoxic therapy; the second patient was prophylactically anticoagulated and had no embolic event...
  4. ncbi request reprint When children die: a seminar series for pediatric residents
    Rochelle Bagatell
    Department of Pediatrics, Steele Memorial Children s Research Center, University of Arizona, Tucson, Arizona 85724, USA
    Pediatrics 110:348-53. 2002
    ..Our goals were to assist residents in acquiring skills needed to care for children at the end of life and to increase their comfort level regarding critical aspects of caring for dying children...
  5. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study
    Rochelle Bagatell
    Department of Pediatrics and Steele Children s Research Center, University of Arizona, Tucson, AZ 85724, USA
    Clin Cancer Res 13:1783-8. 2007
    ....
  6. ncbi request reprint The perfect storm: Torsades de Pointes in a child with leukemia
    Rochelle Bagatell
    Department of Pediatrics, Section of Pediatric Hematology Oncology, University of Arizona Health Sciences Center, Tucson, Arizona 85724, USA
    Pediatr Blood Cancer 49:996-9. 2007
    ..Although the patient suffered cardiac arrest, rapid recognition of TdP and prompt defibrillation resulted in an excellent outcome...
  7. ncbi request reprint Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy
    Rochelle Bagatell
    University of Arizona, Department of Pediatrics and Steele Children s Research Center, Tuscon, AZ, USA
    J Clin Oncol 23:8819-27. 2005
    ..The goal of Pediatric Oncology Group 9243 was to improve outcomes for children with intermediate-risk neuroblastoma (NB)...
  8. ncbi request reprint Altered Hsp90 function in cancer: a unique therapeutic opportunity
    Rochelle Bagatell
    Department of Pediatrics and Hematology Oncology, Arizona Health Sciences Center, Room 5341, 1501 North Campbell Avenue, Tucson, AZ 85724, USA
    Mol Cancer Ther 3:1021-30. 2004
    ....
  9. ncbi request reprint Inhibition of oncogene expression using vector-generated RNA antisense
    L Whitesell
    Department of Pediatrics, University of Arizona, Tucson, Arizona 85724, USA
    Methods 18:296-303. 1999
    ..Lastly, using specific examples, the limitations and potential artifacts associated with antisense vector use in the study of tumorigenesis are discussed...
  10. ncbi request reprint The stress response: implications for the clinical development of hsp90 inhibitors
    Luke Whitesell
    Steele Memorial Children s Research Center, University of Arizona, Tucson, AZ 85724, USA
    Curr Cancer Drug Targets 3:349-58. 2003
    ..Lastly, stress response induction by Hsp90 inhibitors may have therapeutic benefits in non-neoplastic disorders such as heart disease, stroke and neurodegenerative diseases. These benefits are just beginning to be explored...
  11. pmc Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database
    Rochelle Bagatell
    University of Arizona Health Sciences Center, Tucson, AZ, USA
    J Clin Oncol 27:365-70. 2009
    ..To evaluate the outcome of children with low-stage MYCN-amplified neuroblastoma and develop a rational treatment strategy, data from the International Neuroblastoma Risk Group (INRG) database were analyzed...
  12. ncbi request reprint Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors
    Jason Beliakoff
    Steele Memorial Children s Research Center, University of Arizona, Tucson, Arizona 85724, USA
    Clin Cancer Res 9:4961-71. 2003
    ..Therefore, we investigated a ligand-independent approach to hormonal therapy that depletes cellular levels of the receptor by inhibiting the function of Hsp90...
  13. doi request reprint Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors
    R Bagatell
    Department of Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA 19066, USA
    Clin Cancer Res 17:611-9. 2011
    ....
  14. ncbi request reprint Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:832-40. 2003
    ..Recurrent osteosarcoma is a drug-resistant disease with a dismal prognosis. The objective of this Phase II study was to evaluate the activity of ecteinascidin 743 (ET-743) as a salvage therapy in these patients...
  15. doi request reprint Update on imaging and treatment of Ewing sarcoma family tumors: what the radiologist needs to know
    Winnie A Mar
    Department of Radiology, The University of Arizona College of Medicine, Tucson, AZ 85724 5067, USA
    J Comput Assist Tomogr 32:108-18. 2008
    ..This review article provides an update on multimodality imaging characteristics of Ewing sarcoma family tumors. Pathology of this tumor and current trends in medical and surgical treatment are briefly discussed...
  16. ncbi request reprint Increased expression of the Hsp70 cochaperone HspBP1 in tumors
    Deborah A Raynes
    Department of Animal Sciences, University of Arizona, Tucson, AZ 85721, USA
    Tumour Biol 24:281-5. 2003
    ..These studies have shown that HspBP1 is elevated in the tumors examined and therefore could be a new cancer marker...
  17. ncbi request reprint Femoral central venous catheter-associated deep venous thrombosis in children with diabetic ketoacidosis
    Juan A Gutierrez
    Department of Pediatrics, Steele Memorial Children s Research Center, University of Arizona College of Medicine, Tucson, USA
    Crit Care Med 31:80-3. 2003
    ..To describe the incidence of clinical deep venous thrombosis associated with femoral central venous catheters (CVC-DVT) in children with diabetic ketoacidosis (DKA)...
  18. ncbi request reprint Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5410-7. 2007
    ..This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in lymphocytes...
  19. ncbi request reprint A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Clin Cancer Res 13:1789-93. 2007
    ..To determine the recommended phase 2 dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the heat shock protein (Hsp) 90 inhibitor, 17-allylaminogeldanamycin (17-AAG)...
  20. ncbi request reprint Neuroblastoma
    John M Maris
    Children s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4318, USA
    Lancet 369:2106-20. 2007
    ..Finally, we discuss new approaches to treatment, including recently discovered molecular targets that might provide more effective treatment strategies with the potential for less toxicity...

Research Grants1

  1. Hsp90 as a Target for the Treatment of Childhood Cancer
    Rochelle Bagatell; Fiscal Year: 2007
    ..Upon completion of the award period, Dr. Bagatell will be well prepared to move forward as an independent investigator. ..